Low Level of Cerebrospinal Fluid (CSF) Rituximab (RTX) Following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with De Novo Mature B-Cell Non-Hodgkin Lymphoma (B-NHL)

Authors

Matthew J. BarthFollow
Yaya Chu, New York Medical CollegeFollow
Stanton C. Goldman
Jessica Hochberg, New York Medical CollegeFollow
Javier Osterheld
Kenneth Heym
Harshini Mahanti, New York Medical College
Allyson Flower, New York Medical CollegeFollow
Jaclyn Basso
Mitchell S. Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

9-2018

DOI

10.1111/bjh.15536

Journal Title

British Journal of Haematology

Department

Pediatrics

Second Department

Health Behavior and Community Health

Disciplines

Medicine and Health Sciences | Oncology | Pediatrics

Recommended Citation

Barth, M. J., Chu, Y., Goldman, S. C., Hochberg, J., Osterheld, J., Heym, K., Mahanti, H., Flower, A., Basso, J., & Cairo, M. S. (2018). Low Level of Cerebrospinal Fluid (CSF) Rituximab (RTX) Following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with De Novo Mature B-Cell Non-Hodgkin Lymphoma (B-NHL). British Journal of Haematology, 182 (Suppl. 1), 47. https://doi.org/10.1111/bjh.15536